Subscribe To
ACET / Down -53.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Adicet Bio, Inc. (ACET)
ACET News
By Zacks Investment Research
August 9, 2023
Adicet Bio, Inc. (ACET) Reports Q2 Loss, Lags Revenue Estimates
Adicet Bio, Inc. (ACET) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to los more_horizontal
By Zacks Investment Research
May 9, 2023
Adicet Bio, Inc. (ACET) Reports Q1 Loss, Misses Revenue Estimates
Adicet Bio, Inc. (ACET) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to ear more_horizontal
By Seeking Alpha
February 7, 2023
Adicet Bio: Searching For Upside In Cell Therapeutics
Biotechs developing CAR-T cell therapies have seen their valuations plummet in 2022 - making them an intriguing speculative buy opportunity in 2023. T more_horizontal
By Zacks Investment Research
January 25, 2023
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Here is how Adicet Bio, Inc. (ACET) and AlloVir, Inc. (ALVR) have performed compared to their sector so far this year. more_horizontal
By Zacks Investment Research
December 30, 2022
Down -53.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Adicet Bio, Inc. (ACET)
Adicet Bio, Inc. (ACET) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined wit more_horizontal
By Zacks Investment Research
December 14, 2022
Adicet Bio, Inc. (ACET) Loses 47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Adicet Bio, Inc. (ACET) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement more_horizontal
By Pulse2
December 12, 2022
Why The Adicet Bio (ACET) Stock Plummeted Over 35%
The stock price of Adicet Bio (ACET) plummeted over 35% intraday today. This is why. more_horizontal
By Market Watch
December 12, 2022
Adicet Bio shares fall as it shares clinical data about its CAR-T treatment candidate
Adicet Bio's Inc. ACET, -13.13% stock tumbled about 38% in premarket trading on Monday after the company shared data from a Phase 1 clinical trial eva more_horizontal